World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 9, Number 4, August 2018, pages 104-109

Clinicopathological Features of Metastatic Gastric Tumors Originating From Breast Cancer: Analysis of Eleven Cases

**Table 1.** Characteristics of Primary Breast Cancer Patients
Case	Age (years)/sex	Location of cancer	TNM stage	Metastatic organs	Histological type	Residual cancer after surgery
F: female.
1	33/F	Left	IIA	-	Solid-tubular	R0
2	58/F	Left	IV	Liver, adrenal gland, pancreas	Solid-tubular	R2
3	72/F	Right	IIA	-	Scirrous	R0
4	57/F	Left	IIIC	-	Lobular	R1
5	53/F	Left	IV	Bone	Scirrous	R2
6	49/F	Left	IV	Skin	Scirrous/lobular	No surgery
7	64/F	Left	IIIC	-	Scirrous/lobular	R1
8	76/F	Left	IIB		Scirrous	R0
9	63/F	Left	IV	Adrenal gland, skin, brain	Scirrous	R2
10	47/F	Right	IV	Bone, liver	Lobular	R2
11	57/F	Left	I		Lobular	R0

Table 1. Characteristics of Primary Breast Cancer Patients

Case

Age (years)/sex

Location of cancer

TNM stage

Metastatic organs

Histological type

Residual cancer after surgery

F: female.

33/F

Left

IIA

Solid-tubular

58/F

Left

Liver, adrenal gland, pancreas

Solid-tubular

72/F

Right

IIA

Scirrous

57/F

Left

IIIC

Lobular

53/F

Left

Bone

Scirrous

49/F

Left

Skin

Scirrous/lobular

No surgery

64/F

Left

IIIC

Scirrous/lobular

76/F

Left

IIB

Scirrous

63/F

Left

Adrenal gland, skin, brain

Scirrous

47/F

Right

Bone, liver

Lobular

57/F

Left

Lobular

**Table 2.** Characteristics of Patients With Gastric Metastasis From Breast Cancer
Case	Complaint	Macroscopic findings	Metastatic site	Hormonal receptor of biopsy specimen	HER2 status****	Chemotherapy	Metastatic lesion^a	Elapse time^b (months)	Survival time^c (months)	Outcome
^Submucosal tumor. ^Estrogen receptor. Progesterone receptor. **Human epidermal growth factor receptor 2 with Immunohistochemistry test. ^aNumber of metastatic lesion in whole body. ^bFrom diagnosis of breast cancer to gastric metastasis. ^cFrom diagnosis of gastric metastasis.
1	Melena	SMT*	M	-	-	-	Innumerable	19	1	Died
2	Melena	SMT	U	-	-	+	5	40	28	Alive
3	Heartburn	SMT	ML	ER^+, PgR^*+	1+	+	11	100	28	Alive
4	Asymptomatic	SMT	L	ER+, PgR-	1+	-	1	105	19	Alive
5	Melena	Borrmann type 3	M	ER+, PgR-	0	+	5	69	42	Died
6	Asymptomatic	Borrmann type 4	UML	ER+, PgR+	1+	+	Innumerable	39	1	Alive
7	Epigastric pain	Borrmann type 4	UM	ER+, PgR-	1+	+	1	46	37	Died
8	Anorexia	Borrmann type 4	M	ER+, PgR-	1+	+	Innumerable	112	6	Died
9	Vomiting	Borrmann type 4	L	ER+, PgR+	-	-	Innumerable	58	4	Died
10	Asymptomatic	Borrmann type 4	M	ER+	-	+	12	61	29	Died
11	Epigastric pain	Borrmann type 4	ML	ER+, PgR-	1+	+	2	181	26	Died

Table 2. Characteristics of Patients With Gastric Metastasis From Breast Cancer

Case

Complaint

Macroscopic findings

Metastatic site

Hormonal receptor of biopsy specimen

HER2 status****

Chemotherapy

Metastatic lesion^a

Elapse time^b (months)

Survival time^c (months)

Outcome

^*Submucosal tumor. ^**Estrogen receptor. ***Progesterone receptor. ****Human epidermal growth factor receptor 2 with Immunohistochemistry test. ^aNumber of metastatic lesion in whole body. ^bFrom diagnosis of breast cancer to gastric metastasis. ^cFrom diagnosis of gastric metastasis.

Melena

SMT*

Innumerable

Died

Melena

SMT

Alive

Heartburn

SMT

ER^**+, PgR^***+

100

Alive

Asymptomatic

SMT

ER+, PgR-

105

Alive

Melena

Borrmann type 3

ER+, PgR-

Died

Asymptomatic

Borrmann type 4

UML

ER+, PgR+

Innumerable

Alive

Epigastric pain

Borrmann type 4

ER+, PgR-

Died

Anorexia

Borrmann type 4

ER+, PgR-

Innumerable

112

Died

Vomiting

Borrmann type 4

ER+, PgR+

Innumerable

Died

Asymptomatic

Borrmann type 4

ER+

Died

Epigastric pain

Borrmann type 4

ER+, PgR-

181

Died

**Table 3.** Comparison of Characteristics Between Gastric Cancer (GC)-Like Lesion and SMT
	GC -like lesion (N = 7)	SMT (N = 4)	P value
Age, years, median (range)	57 (49 - 76)	57 (33 - 72)	0.925
Symptomatic (%)	5 (71)	3 (75)	1
Peritoneal metastasis (%)	6 (86)	0 (0)	0.0152
Invasive lobular carcinoma (%)	4 (57)	1 (25)	0.545
Multiple lesions (%)	6 (86)	2 (50)	0.491
Chemotherapy after diagnosis of gastric metastasis (%)	6 (86)	2 (50)	0.491
Survival time from diagnosis of breast cancer, months, median (range)	90 (40 - 207)	96 (20 - 127)	1
Elapse time from diagnosis of breast cancer to gastric metastases, months, median (range)	61(39 - 181)	70(19 - 106)	0.571
Survival time from gastric metastasis, months, median (range)	26(4 - 37)	23(1 - 28)	0.571

Table 3. Comparison of Characteristics Between Gastric Cancer (GC)-Like Lesion and SMT

GC -like lesion (N = 7)

SMT (N = 4)

P value

Age, years, median (range)

57 (49 - 76)

57 (33 - 72)

0.925

Symptomatic (%)

5 (71)

3 (75)

Peritoneal metastasis (%)

6 (86)

0 (0)

0.0152

Invasive lobular carcinoma (%)

4 (57)

1 (25)

0.545

Multiple lesions (%)

6 (86)

2 (50)

0.491

Chemotherapy after diagnosis of gastric metastasis (%)

6 (86)

2 (50)

0.491

Survival time from diagnosis of breast cancer, months, median (range)

90 (40 - 207)

96 (20 - 127)

Elapse time from diagnosis of breast cancer to gastric metastases, months, median (range)

61(39 - 181)

70(19 - 106)

0.571

Survival time from gastric metastasis, months, median (range)

26(4 - 37)

23(1 - 28)

0.571